Joel A Sincavage

Array ( [id] => 4813832 [patent_doc_number] => 20080194463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-08-14 [patent_title] => 'Antibacterial antisense oligonucleotide and method' [patent_app_type] => utility [patent_app_number] => 11/803107 [patent_app_country] => US [patent_app_date] => 2007-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 38552 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0194/20080194463.pdf [firstpage_image] =>[orig_patent_app_number] => 11803107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5368621 [patent_doc_number] => 20090306180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => 'COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB' [patent_app_type] => utility [patent_app_number] => 12/299764 [patent_app_country] => US [patent_app_date] => 2007-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 137040 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0306/20090306180.pdf [firstpage_image] =>[orig_patent_app_number] => 12299764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5368798 [patent_doc_number] => 20090306357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => 'COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR' [patent_app_type] => utility [patent_app_number] => 12/299583 [patent_app_country] => US [patent_app_date] => 2007-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 137602 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0306/20090306357.pdf [firstpage_image] =>[orig_patent_app_number] => 12299583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5368620 [patent_doc_number] => 20090306179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => 'COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR' [patent_app_type] => utility [patent_app_number] => 12/299609 [patent_app_country] => US [patent_app_date] => 2007-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 137509 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0306/20090306179.pdf [firstpage_image] =>[orig_patent_app_number] => 12299609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5368446 [patent_doc_number] => 20090306005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => 'COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF PCSK9' [patent_app_type] => utility [patent_app_number] => 12/299572 [patent_app_country] => US [patent_app_date] => 2007-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 137516 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0306/20090306005.pdf [firstpage_image] =>[orig_patent_app_number] => 12299572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8114765 [patent_doc_number] => 08158598 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-04-17 [patent_title] => 'Compositions and their uses directed to PTPR alpha' [patent_app_type] => utility [patent_app_number] => 12/299610 [patent_app_country] => US [patent_app_date] => 2007-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 18116 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/158/08158598.pdf [firstpage_image] =>[orig_patent_app_number] => 12299610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8103909 [patent_doc_number] => 08153604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-04-10 [patent_title] => 'CNS-tumor treatment method and composition' [patent_app_type] => utility [patent_app_number] => 12/297301 [patent_app_country] => US [patent_app_date] => 2007-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 23 [patent_no_of_words] => 7937 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/153/08153604.pdf [firstpage_image] =>[orig_patent_app_number] => 12297301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5586262 [patent_doc_number] => 20090105464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-23 [patent_title] => 'PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND DNA' [patent_app_type] => utility [patent_app_number] => 11/737521 [patent_app_country] => US [patent_app_date] => 2007-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5807 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0105/20090105464.pdf [firstpage_image] =>[orig_patent_app_number] => 11737521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5085862 [patent_doc_number] => 20070275913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-11-29 [patent_title] => 'COMPOSITIONS AND THEIR USES DIRECTED TO HEPCIDIN' [patent_app_type] => utility [patent_app_number] => 11/734562 [patent_app_country] => US [patent_app_date] => 2007-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 16357 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20070275913.pdf [firstpage_image] =>[orig_patent_app_number] => 11734562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5102056 [patent_doc_number] => 20070185318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-08-09 [patent_title] => 'siRNA targeting connexin 43' [patent_app_type] => utility [patent_app_number] => 11/731894 [patent_app_country] => US [patent_app_date] => 2007-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 34713 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0185/20070185318.pdf [firstpage_image] =>[orig_patent_app_number] => 11731894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5485869 [patent_doc_number] => 20090275634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-05 [patent_title] => 'ANTISENSE OLIGONUCLEOTIDES AGAINST ACETYLCHOLINESTERASE FOR TREATING INFLAMMATORY DISEASES' [patent_app_type] => utility [patent_app_number] => 12/296455 [patent_app_country] => US [patent_app_date] => 2007-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9028 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20090275634.pdf [firstpage_image] =>[orig_patent_app_number] => 12296455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5028922 [patent_doc_number] => 20070270369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-11-22 [patent_title] => 'USE OF HEPATITIS B X-INTERACTING PROTEIN (HBXIP) IN MODULATION OF APOPTOSIS' [patent_app_type] => utility [patent_app_number] => 11/691393 [patent_app_country] => US [patent_app_date] => 2007-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 22828 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0270/20070270369.pdf [firstpage_image] =>[orig_patent_app_number] => 11691393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10844552 [patent_doc_number] => 08871729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-28 [patent_title] => 'Treatment of CNS conditions' [patent_app_type] => utility [patent_app_number] => 12/293230 [patent_app_country] => US [patent_app_date] => 2007-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 12831 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12293230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5028921 [patent_doc_number] => 20070270368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-11-22 [patent_title] => 'COMPOSITIONS AND METHODS FOR MODULATION OF MCL-1 EXPRESSION' [patent_app_type] => utility [patent_app_number] => 11/687535 [patent_app_country] => US [patent_app_date] => 2007-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22401 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0270/20070270368.pdf [firstpage_image] =>[orig_patent_app_number] => 11687535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8214266 [patent_doc_number] => 08193159 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-06-05 [patent_title] => 'MCP-1 binding nucleic acids' [patent_app_type] => utility [patent_app_number] => 12/279183 [patent_app_country] => US [patent_app_date] => 2007-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 38882 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/193/08193159.pdf [firstpage_image] =>[orig_patent_app_number] => 12279183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 185296 [patent_doc_number] => 07645732 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-01-12 [patent_title] => 'Treating hepatitis C virus infection' [patent_app_type] => utility [patent_app_number] => 11/657856 [patent_app_country] => US [patent_app_date] => 2007-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3201 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/645/07645732.pdf [firstpage_image] =>[orig_patent_app_number] => 11657856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4797870 [patent_doc_number] => 20080009456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-01-10 [patent_title] => 'ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION' [patent_app_type] => utility [patent_app_number] => 11/618167 [patent_app_country] => US [patent_app_date] => 2006-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26756 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0009/20080009456.pdf [firstpage_image] =>[orig_patent_app_number] => 11618167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8446301 [patent_doc_number] => 08288354 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-10-16 [patent_title] => 'Natural antisense and non-coding RNA transcripts as drug targets' [patent_app_type] => utility [patent_app_number] => 12/159607 [patent_app_country] => US [patent_app_date] => 2006-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 25 [patent_no_of_words] => 40742 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12159607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8538180 [patent_doc_number] => 08313901 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-11-20 [patent_title] => 'Methods and compositions related to the modulation of riboswitches' [patent_app_type] => utility [patent_app_number] => 12/158168 [patent_app_country] => US [patent_app_date] => 2006-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 19523 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12158168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5404621 [patent_doc_number] => 20090239935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-09-24 [patent_title] => 'RNA-HELICASE AS A MARKER FOR RARE TUMORS' [patent_app_type] => utility [patent_app_number] => 12/097662 [patent_app_country] => US [patent_app_date] => 2006-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9654 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0239/20090239935.pdf [firstpage_image] =>[orig_patent_app_number] => 12097662 [rel_patent_id] =>[rel_patent_doc_number] =>)